Ranjana Srivastava
+91-9335-819-609
ranjana@biotechresearch.in
Former Head – Microbiology Division
Central Drug Research Institute, Lucknow
An astute professional with 38 years of rich & qualitative experience in scientific domain. A blend of
successful science & people management – which includes building the vision of the department, people
management & future projection, appraisals of development of people within team and department.
Over the years, have participated in national & international committees, meetings & conferences,
publications in journals; with an aspiration to contribute to the overall scientific development and growth.
Core Strengths
* Microbiology
* Molecular Biology
* Biotechnology
Professional Background
 Scientist G (till 2011) with Central Drug Research Institute, India
 Post Doctorate Research Associate with Brown University, Providence, USA from 1978-82
 University of Brussels, Belgium from 1972-74
Deputation abroad
 DBT Overseas Research Associate-ship with Center for Vaccine Development, Baltimore, USA
In 1988
 Visiting Scientist (Indo – US VAP) with Center for Vaccine Development, Baltimore, USA in
1990, 1991, 1992 & 1993
 Visiting Scientist (Indo – French) with Institute Pasteur de Lille, Lille, France in 2002 & 2004
Areas of research
 Genetics of E. coli RNA Polymerase
 Pathogenesis of Vibrio cholerae
 Molecular basis for band and interband pattern in polytene chromosomes of fungus fly Sciara
coprophila
 Cellulose degradation
 Tuberculosis
Significant Milestones
Development of a DNA diagnostic probe for Tuberculosis
By molecular cloning and DNA hybridization, a repetitive sequence specific to
Mycobacterium
tuberculosis was selected which was developed as diagnostic probe to detect tubercle bacilli in clinical
fluids. The probe was sequenced to establish the novelty, uniqueness and specificity was established with
thousands of clinical isolates of M. tuberculosis and clinical specimens and patent in India, Europe and
USA was obtained. PCR based diagnostic assay detects M.tuberculosis DNA which has been brought to
Real Time PCR platform with Taqman technology. It has been commercialized as “MycoView MTB PCR
detection kit” by Central Drug Research Institute (CDRI).
Development of surrogate screens for high throughput screening of anti-TB compounds
User friendly nonhazardous rapid screens have been developed to preselect active anti-TB compounds
using apathogenic, non hazardous M. bovis BCG and M. aurum as surrogate strains and GFP and firefly
luciferase as reporters. Use of these reporter strains allow to select an active compound within 48 h
which were further validated in isolation on recombinant M.tuberculosis expressing GFP or luciferase.
M. aurum as surrogate strain of M. tuberculosis for screening FasII inhibitors developed using proteinprotein interaction and bacterial two hybrid system.
Mining new drug targets from TB genome by genetic approaches
Branched chain amino acids (BCAA; isoleucine, leucine and valine; ILV) biosynthesis pathway was explored
for novel targets for the development of new anti TB drugs as BCAA auxotrophs of mycobacteria fail to
grow in the host. Another approach used in vivo expression technology (IVET) and in vivo induced
antigen technology (IVIAT) for selection of genes expressed during infection of M. tuberculosis in
macrophages, mice and human. A novel vector was developed with a bicistronic reporter for cloning of
functional promoters during infection in macrophages and in mice. The bicistronic reporter is a
transcriptional fusion of promoterless green fluorescent protein and kanamycin resistance genes. The
selection strategy lies in selection of fluorescent kanamycin resistant clones surviving in the macrophages/
lungs after giving kanamycin assault to macrophage/ mice. One of the gene identified by IVIAT, Rv3303c
has been characterized as virulence factor which protects TB bacilli against oxidative stress and is
upregulated during infection ex vivo and in vivo.
New chemical entities
A number of synthetic lead anti-TB compounds were identified which are classified as (i) glycosylated
propanamides (b) glycosylated and substituted ureas and thioureas (c) diglycoxylated diaminoalcohol (d)
substituted amino glycosidated popanoates (e) phenyl cyclopropyl methanomes (f) thiazidine thiones (g)
galactopyranosylated amino alcohols (h) daryloxy methane phenanthrenes (i) ICL /arylalkyl dideoxy
glucopyranisides . IPR has been secured and published .
Development of in vivo murine infection model for M. fortuitum
A murine infection model for M. fortuitum was developed which displays active and chronic infection. The
infection produce characteristic visible disease symptoms which disappeared during chronic infection.
Administration of drug resulted in loss of symptoms in infected mice thus making it a rapid in vivo
screening model and was used to screen compounds active against NTM infection.
Scholastics & Awards
Ph.D. students guided
17
MD Thesis
6
Awards
Shakuntala Amirchand Prize of ICMR
CSIR New Idea Fund
1986
2005
Publications
1.
R. Srivastava, C. Toussaint and J.P. Lecocq 1974. A rifampicin resistant mutation of E. coli whose
phenotypic expression is dependent on the composition of the medium and recA allele. Mutation
Res. 23, 25.
2.
R. Srivastava, V.B. Sinha, B.S. Srivastava. 1979.
Re-evaluation of antibacterial and anti-toxin
immunities in experimental cholera. Ind. J. Med. Res. 70, 369.
3.
B.S. Srivastava, V.B. Sinha, R. Srivastava. 1979. Attenuated recombinant strains of Vibrio cholerae for
oral immunization. Bull. Wld. Hlth. Org. 57, 649.
4.
R. Srivastava, V.B. Sinha, B.S. Srivastava. 1980. Events in the pathogenesis of experimental cholera:
role of bacterial adherence and multiplication. J. Med. Microbiol. 13, 1.
5.
R. Srivastava, B.S. Srivastava. 1980. Isolation of a non-adhesive mutant of Vibrio cholerae and
chromosomal localization of the gene controlling mannose sensitive adherence to intestinal mucosa.
J. Gen. Microbiol. 117, 275.
6.
A.A. Khan, R. Srivastava, V.B. Sinha, B.S. Srivastava. 1985. Regulation of toxin biosynthesis by plasmids
in vibrio cholerae. J. Gen. Microbiol. 131, 2653.
7.
R. Srivastava, A.A. Khan, B.S. Srivastava. 1985. Immunological detection of cloned antigenic genes of
Vibrio cholerae in Escherichia coli. Gene, 40, 267.
8.
R. Srivastava, V.B. Sinha, B.S. Srivastava 1989 . Chromosomal; transfer and in vivo cloning of genes in
Vibrio cholerae using RP4::mini-Mu. Gene 75, 253.
9. A.W. Kerrebroeck, R. Srivastava, S.A. Gerbi. 1989. Isolation and characterization of ribosomal DNA
variants from Sciara coprophila. J. Mol. Biol. 210, 1.
10. J.R. Czezulin, R. Srivastava, B.S. Srivastava, J.B. Kaper. 1990. Characterization of a possible colonizing
factor of Vibrio cholerae. 01. Proc. Amer. Soc. Microbiol. 108.
11. R. Srivastava, R. Bharti, A.K. Srivastava. 1990. Characterization of a novel cellobiase from Bacillus
subtilis and expression of its structural gene in Escherichia coli. Biotech. Lett. 12, 541.
12. R. Srivastava, S. S. Ali, B. S. Srivastava. 1991. Cloning of xylanase gene of Streptomyces flavogriseus in
Escherichia coli and bacteriophage lambda induced lysis for the release of cloned enzyme. FEMS
Microbiol Lett. 78, 201.
13. C.K.M. Tripathi, S.S. Ali, R. Srivastava. 1992. Characterization of xylanase activity of Streptomyces
wedmorensis. Ind. J. Exptl. Biol. 30, 741.
14. A. Jacob, R. Srivastava, V.B. Sinha, M.K. Sahib, J.B. Kaper, B.S. Srivastava. 1993. Identification of a 33
kDa antigen associated with an adhesive and colonizing strain of Vibrio cholerae el tor and its role in
protection. Vaccine, 11, 376.
15. V.B. Sinha, A. Jacob, R. Srivastava ,J.B. Kaper, B.S. Srivastava. 1993. Identification of the flagellar
antigens of Vibrio cholerae el tor and their role in protection. Vaccine, 11, 372A.
16. R. Srivastava, A.K. Srivastava. 1993. Characteriozation of a bacterial xylanase resistant to repression
by glucose and xylose. Biotech. Lett. 15, 847.
17. K. Krishna Kumar, R, Srivastava, V.B. Sinha, J. Mechalski, J.B. Kaper, B.S.Srivastava. 1994. recA
mutations reduce adherence and colonization of classical and el tor strains of Vibrio cholerae.
Microbiology 140, 1217.
18. S.N. Singh, R. Srivastava, V.B. Sinha, B.S. Srivastava. 1994. A 53 kDa protein of Vibrio cholerae classical
strain 0395 involved in intestinal colonization. Microbial Pathogenesis 17, 69.
19. R. Srivastava, G. Prasanna Kumar, K.K. Srivastava. 1995. Genetic construction of a cellulolytic
Escherichia coli. Gene 164, 185.
20. D. Kumar, B.S. Srivastava, N. B. Singh, R. Srivastava. 1996. Identification of a 25 kDa
protein of
Mycobacterium bovis BCG to distinguish BCG from Mycobacterium tuberculosis. J. Clin. Microbiol. 34,
224.
21. R. Srivastava, D. Kumar, P Subramaniam, B.S. Srivastava. 1997. - galactosidase reporter system in
mycobacteria and its application in rapid antimycobacterial drug screening. Biochem. Biophys. Res.
Commun. 235, 602.
22. R. Srivastava, D. Kumar, B. S. Srivastava.1997.
Recombinant Mycobacterium aurum expressing
Escherichia coli -galactosidase in high through put screening of antituberculosis drugs. Biochem.
Biophys. Res. Commun. 240, 536.
23. V.P. Bondre, R. Srivastava, V.B. Sinha, B.S. Srivastava. 1997. Screening of TnphoA mutants of Vibrio
cholerae 0139 for identification of antigens involved in colonization. J. Med. Microbiol. 46, 1007.
24. A.Shukla, M.P. Dubey, R.Srivastava, B.S. Srivastava .1998. Differential expression of proteins during
healing of cutaneous wounds in experimental and normal and chronic models. Biochem. Biophys. Res.
Commun. 244, 434.
25. D. Kumar, B.S. Srivastava, R. Srivastava. 1998. Genetic rearrange-ments leading to disruption of
heterologous gene
expression in mycobacteria: An observation with -galactosidase in
Mycobacterium smegmatis. Vaccine, 16, 1212.
26. R. Srivastava, D.K. Deb, K.K. Srivastava, C. Locht, B. S. Srivastava. 1998. Green fluorescent protein as a
reporter in rapid screening of antituberculosis compounds in vitro and in macrophages. Biochem.
Biophys. Res. Commun.. 253, 431.
27. R. Srivastava, B.S. Srivastava. 2000. Tuberculosis vaccines. IDrugs, 3, 408.
28. D.K.Deb, K.K.Srivastava, R. Srivastava, B.S. Srivastava. 2000. Bioluminescent Mycobacterium aurum
expressing firefly luciferase for rapid and high throughput screening of antimycobacterial drugs in
vitro and in infected macrophages. Biochem. Biophys. Res. Comm. 279, 457.
29. R. Srivastava, B.S.Srivastava. 2000. Tuberculosis vaccines: a critical role for T-cells. Curr. Opinion
Anti-inflammatory & Immunomodulatory Investigational Drugs 2 (2), 100.
30. M. Waskar, D. Kumar, A. Kumar, R. Srivastava. 2000. Ioslation of a novel insertion sequence from
Mycobacterium fortuitum using a trap vector based on inactivation of a lacZ reporter gene.
Microbiology, 146, 1157.
31. R.Prasad, S.K. Lath, P.K., Mukerji, S.K., Agarwal, R. Srivastava,. 2001.
Clinical utility of Polymerase
chain reaction in patients of Pulmonary Tuberculosis. Ind. J. Tub. 48, 135.
32. R. Pathak, C. S. Pant, A. K. Shaw, A. P. Bhaduri, A. N. Gaikwad, S. Sinha, A. Srivastava, K. K. Srivastava,
V. Chaturvedi, R. Srivastava, B. S. Srivastava. 2002. Baylis-Hillman Reaction: Convenient ascending
syntheses and biological evaluation of Acyclic Deoxy monosaccharides as potential antimycobacterial
agents. Biorg. Med. Chem. 10, 3187.
33. R. Pathak, A. K. Shaw, A. P. Bhaduri, K. V. G. Chandrasekhar, A. Srivastava, K. K. Srivastava, V.
Chaturvedi, R. Srivastava, B. S. Srivastava, S. Arora, S. Sinha. 2002. Higher acyclic nitrogen containing
deoxy sugar derivatives: a new lead in the generation of antimycobacterial chemotherapeutics. Biorg.
Med. Chem. 10, 1695.
34. R.P. Tripathi, R. Tripathi, V.K. Tiwari, L. Bala, S. Sinha, S.A. Srivastava, R. Srivastava, B.S. Sivastava.
2002. Synthesis of glycosylated B-amino acids as new class of antitubercular agents. Eur. J. Med.
Chem. 37, 773.
35. D.K. Deb, P. Dahiya, K.K. Srivastava, R. Srivastava. B.S. Srivastava. 2002. Selective identification of
new therapeutic targets of Mycobacterium tuberculosis by IVIAT approach. Tuberculosis 82, 175.
36. D. Katiyar, V.K. Tiwari, R.P. Tripathi, A. Srivastava, V. Chaturvedi, R. Srivastava., B.S. Srivastava. 2003.
Synthesis an antimycobacterial activity of 3,5-disubstituted thiadiazine thiones. Bioorg. Med. Chem.
11, 4369.
37. A.Mishra, A., R. Srivastava, C. Pruzzo, B.S. Srivastava. 2003. Mutation in tcpR gene (Vc0832) of Vibrio
cholerae O1 causes loss of tolerance to high osmolarity and affects colonization and virulence in infant
mice. J. Med. Microbiol. 52, 1.
38. P. Prem Raj, S. Srivastava, S. K. Jain, B. S. Srivastava, R. Srivastava.. 2003. Protection by live
Mycobacterium habana cvaccine against Mycobacterium tuberculosis H37Rv challenge in mice. Indian
J. Med. Res. 117, 139.
39. G. Panda, Shagufta , J. K. Mishra, V. Chaturvedi, A. K. Srivastava, R. Srivastava, B.S. Srivastava 2004.
Diaryloxy methano phenanthrenes: a new class of antituberculosis agents. Bioorg. Med. Chem. 12 .
5269.
40. D. Katiyar, V.K. Tiwari, N. Tiwari, S.S. Verma, S. Sinha, A. Gaikwad, A. Srivastava, V., Chaturvedi, R.
Srivastava, B.S. Srivastava and R.P. Tripathi . 2005. Synthesis of antimycobacterial activity of Glosylated
Aminesand Amino Alcohols.. Eur. J. Med. Chem.40,(2005) 351.
41. M. Zampini, C. Pruzzo, V.P. Bondre, R. Tarsi, M. Cosmo, A. Bacciaglia, A. Chabbra, R. Srivastava, B.S.
Srivastava.. 2005. Vibrio cholerae persistence in aquatic environments and colonization of intestinal
cells: involvement of a common adhesion mechanism. FEMS Microbiol. Lett. 244 , 267.
42. R.P.S. Parti, S. Srivastava, R. Gachhui, K.K. Srivastava, R. Srivastava. 2005. Murine infection model for
Mycobacterium fortuitum. Microbes and Infection. 7, 349.
43. R. Srivastava, D. Kumar, M.N. Waskar, M. Sharma, V.M. Katoch, B.S. Srivastava. 2006. Identification of
a repetitive sequence belonging to a PPE gene of Mycobacterium tuberculosis and its use in diagnosis
of tuberculosis . J. Med. Microbiol. 55, 1071.
44. R. K. Asthana,, A. Srivastava, A. P. Singh, Deepali, S. P. Singh, G.l Nath, R. Srivastava, B. S. Srivastava.
2006. Identification of an antimicrobial entity from the cyanobacterium Fischerella sp. isolated from
bark of Azadirachta indica (Neem) tree . J. Applied Phycology 18 (1), 33.
45. P. Akhtar, S. Srivastava, A. Srivastava, M. Srivastava,
B. S. Srivastava, R. Srivastava 2006. Rv3303c of
Mycobacterium tuberculosis protects tubercle bacilli against oxidative stress in vivo and contributes to
virulence in mice. Microbes and infection 8, 2855.
46. V. Srivastava, C. Rouanet, R. Srivastava, B. Ramalingam, C. Locht, B.S. Srivastava. 2007. Macrophage
specific M. tuberculosis genes identified by green fluorescent protein and kanamycin resistance
selection. Microbiology 153 (Pt 3) 659.
47. M. Saquib, M. K. Gupta, R. Sagar, Y. S. Prabhakar , A. K. Shaw, R. Kumar, P. R. Maulik, A. Gaikwad, S.
Sinha, A. K. Srivastava, V. Chaturvedi, R. Srivastava, B.S. Srivastava.2007. C-3 Alkyl/Arylalkyl-2,3dideoxy hex-2-enopyranosides as anti- tubercular agents: Synthesis, Biological Evaluation and QSAR
study. J. Med. Chem., 50, 2942.
48. V. Srivastava, A. Jain, B.S. Srivastava, R. Srivastava. 2008. Selection of genes of
Mycobacterium
tuberculosis upregulated during residence in lungs of infected mice. Tuberculosis (Edinb). 88 (3) 171.
49. A. Saxena, V. Srivasrtava, R. Srivastava, B.S. Srivastava. 2008. Identification of genes of Mycobacterium
tuberculosis upregulated during anaerobic persistence by fluorescence and kanamycin resistance
selection. Tuberculosis (Edinb), 88 (6) 518.
50. R.P.S. Parti, R. Shrivastava, S. Srivastava, A.R. Subramanian, R. Roy, B.S. Srivastava, R. Srivastava.
2008. . A transposon insertion mutant of Mycobacterium fortuitum attenuated in virulence and
persistence in a murine infection model that is complemented by Rv3291c of Mycobacterium
tuberculosis. Microbial Pathogenesis. 45(5-6), 370.
51. A. Gupta, S. Bhakta, S. Kundu, M. Gupta, B.S. Srivastava, R. Srivastava. 2009. Fast-growing, noninfectious and intracellularly surviving drug-resistant Mycobacterium aurum: a model for highthroughput antituberculosis drug screening. J. Antimicrob. Chemotherapy 64(4), 774.
52. J. Kundu, R. Mazumdar,
R. Srivastava, B.S. Srivastava. 2009.
Intranasal immunization with
recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio
cholerae 01 challenge. Fems Immunol Med Microbiol. 56(2), 179.
53. R.K. Asthana, A. Deepali, M.K. Tripathi, A. Srivastava, A.P. Singh, S.P. Singh, G. Nath, R. Srivastava, B.S.
Srivastava. 2009. Isolation and identification of a new antibacterial entity from the Antarctic
cyanobacterium Nostoc CCC 537. Journal of Applied Phycology 21(1), 81.
54. V. R. Reddy, P. Venkat Reddy, N. N. Mishra, P.K. Shukla, G. Yadav, R. Srivastava, A. K. Shaw. 2010.
Synthesis and biological evaluation of glycal-derived novel tetrahydrofuran 1,2,3-triazoles by 'click'
chemistry. Carbohydr Res. 345(11), 1515.
55. R. K. Gupta, B.S. Srivastava, R. Srivastava. 2010. Comparative expression analysis of rpf-like genes of
Mycobacterium tuberculosis H37Rv under different physiological stress and growth conditions.
Microbiology, 156 , 2714.
56. Haldar S, Bose M, Chakrabarti P, Daginawala HF, Harinath BC, Kashyap RS, Kulkarni S, Majumdar A,
Prasad HK, Rodrigues C, Srivastava R, Taori GM, Varma-Basil M, Tyagi JS.. 2011. Improved laboratory
diagnosis of tuberculosis - The Indian experience.Tuberculosis (Edinb). Julyl 15. PMID: 21764383
57. Singh VK, Srivastava V, Singh V, Rastogi N, Roy R, Shaw AK, Dwivedi AK, Srivastava R, Srivastava BS.
2011. Overexpression of Rv3097c in Mycobacterium bovis BCG abolished the efficacy of BCG vaccine
to protect against Mycobacterium tuberculosis infection in mice.Vaccine. 2011;29(29-30):4754-60.
58. Saquib M, Husain I, Sharma S, Yadav G, Singh VK, Sharma SK, Shah P, Siddiqi MI, Kumar B, Lal J, Jain
GK, Srivastava BS, Srivastava R, Shaw AK.2011. 2,3-dideoxy hex-2-enopyranosid-4-uloses as promising
new anti-tubercular agents: design, synthesis, biological evaluation and SAR studies.Eur J Med Chem.
2011 46(6):2217-23.
59. Singh V, Chandra D, Srivastava BS, Srivastava R 2011. Biochemical and transcription analysis of
acetohydroxyacid synthase isoforms in Mycobacterium tuberculosis identifies these enzymes as
potential targets for drug development.Microbiology. ;157(Pt 1):29-37.
60. Singh V, Chandra D, Srivastava BS, Srivastava R 2011. Downregulation of Rv0189c, encoding a
dihydroxyacid dehydratase, affects growth of Mycobacterium tuberculosis in vitro and in mice.
Microbiology. ;157(Pt 1):38-46.
61. Sharma SK, Moe TS, Srivastava R, Chandra D, Srivastava BS. 2011. Functional characterization of
VC1929 of Vibrio cholerae El Tor: role in mannose-sensitive haemagglutination, virulence and
utilization of sialic acid. Microbiology.;157(Pt 11):3180-6.
62. Roy KK, Singh S, Sharma SK, Srivastava R, Chaturvedi V, Saxena AK. 2011. Synthesis and biological
evaluation of substituted 4-arylthiazol-2-amino derivatives as potent growth inhibitors of replicating
Mycobacterium tuberculosis H₃₇Rv. Bioorg Med Chem Lett.;21(18):5589-93.
63. Kashyap VK, Gupta RK, Shrivastava R, Srivastava BS, Srivastava R, Parai MK, Singh P, Bera S, Panda G.
2012. In vivo activity of thiophene-containing trisubstituted methanes against acute and persistent
infection of non-tubercular Mycobacterium fortuitum in a murine infection model. J Antimicrob
Chemother. ;67(5):1188-97.
Patents Granted
1. Mycobacterium tuberculosis specific DNA International fragment. Ranjana Srivastava, Deepak
Kumar, B.S. Srivastava.
US Patent no. 6,242,585 B1, 5. 6. 2001.
2. Mycobacterium tuberculosis specific DNA fragment. Ranjana Srivastava, Deepak Kumar, B.S.
Srivastava.
US Patent no. 6114514, 05. 09. 2000
3. Mycobacterium tuberculosis specific DNA fragment. Ranjana Srivastava, Deepak Kumar, B.S.
Srivastava.
European Patent EP0945462.; Germany, England, France and Netherland. 08/02/2006
4. Antitubercular extracts of Salicornia brachiata. M. R. Rathod, B. D. Shethia, J. B. Pandya, P. K. Ghosh,
P.J. Dodia, Brahm S. Srivastava, Ranjana Srivastava, A. Srivastava, V. Chaturvedi, M. Vairamani.
U S patent 20070020351, 25.01. 2007.
5.
Herbal extracts of Salicornia species, process of preparation thereof, use thereof against
tuberculosis preparation thereof, use thereof against tuberculosis. M. R. Rathod, B. D. Shethia, J.
B.Pandya, P. K. Ghosh, P. J. Dodia, Brahm S. Srivastava, Ranjana Srivastava, A. Srivastava, V.
Chaturvedi
US Patent 20070248704, . 25. 10. 2007.
National Patents Granted
1.
A process for the production of bifunctional glucose and cellobiose inhibition resistant cellulase from
a new microorganism Bacillus subtilis. R. Srivastava and B.S. Srivastava.
Patent no 187232; 29.9.2002
2.
A process for the production of bifunctional cellulase from Escherichia coli. R. Srivastava , K.K.
Srivastava and B.S. Srivastava.
Patent no. 187959; 3.7. 2003.
3.
A process for the preparation of novel combinatorial library of 3-substituted amino-3-glycosylated
propanoates useful as antifungal and antibacterial agents . R.P. Tripathi, B. Kundu, P. K. Shukla, S.
Sinha, Ranjana Srivastava, A. Srivastava, V. Chaturvedi, K. K. Srivastava, Brahm Shanker Srivastava.
Patent no. 194984; 17.03.2006
4.
A novel combinatorial library of 3-substituted amino-3-glycosylated propanamides useful as
antifungal and antibacterial agents. R. P. Tripathi, P. K. Shukla, S. Sinha, Ranjana Srivastava, A.
Srivastava, V. Chaturvedi, K. K. Srivastava, Brahm Shanker Srivastava.
Patent no. 196956; 23.06.2006.
5.
A process for the preparation of novel combinatorial library of N1-glycosylated and N3- substituted
ureas and thioureas useful as antitubercular agents . R. P. Tripathi, V. K. Tiwari, R. C. Mishra, Ranjana
Srivastava, S. Sinha, A. Srivastava, V. Chaturvedi, K. K. Srivastava, Brahm Shanker Srivastava.
Patent no. 199556; 16.10.2006.
6.
A process for the preparation of novel N1 , N n di glycosylated diaminoalcohol useful in chemotherapy
of tubercular infections. R. P. Tripathi, V. K. Tiwari, N. Tewari, Ranjana Srivastava, A. Srivastava, V.
Chaturvedi, K.K. Srivastava, S. Sinha, B. S. Srivastava,
Patent no. 199829; 28.9.2007.
National Patents Filed
1.
A process for the preparation of 1,3,5-thiazidin--2-thiones useful in chemotherapy of tubercular
infections. R. P. Tripathi, D. Katiyar, Ranjana Srivastava, A. Srivastava, V. Chaturvedi, K. K. Srivastava,
Brahm Shanker Srivastava.
1098 DEL 2004; 6.11.2004.
2. Novel 1,3,5-thiazidine-2-thiones useful in chemotherapy of tubercular infections. R. P. Tripathi, D.
Katiyar, Ranjana Srivastava, A. Srivastava, V. Chaturvedi, K. K. Srivastava, Brahm Shankar Srivastava
1100 DEL 2004; 6.11.2004.
3. A process for the synthesis of Novel Phenyl Cyclopropyl methanones useful as antitubercular agents. R.
Grover, R.C. Mishra, S.S. Verma, R.P. Tripathi, Raja Roy, A.K. Dwivedi, S. Singh, R. Srivastava, A.
Srivastava, V. Chaturvedi, Manju Y. Krishnan, B. S. Srivastava.
0636 DEL/ 2004; 31.3.2004 .
4. Herbal extracts of Salicornia species, process of preparation thereof, use thereof against tuberculosis.
M.R. Rathod, B.S. Shetheia, J.B. Pandeya, P.K. Ghosh, P.J. Dodia, B.S. Srivastava, R. Srivastava, A.
Srivastava, V. Chaturvedi. N 034/ NF/2003
4. Two assays to determine the activity of Isocitrate lyase from Mycobacterium tuberculosis and other
mycobacteria . Manish Gupta, Ranjana Srivastava, Brahm S. Srivastava INF/PAT/09/2004
5. Mycobacterium tuberculosis specific DNA probes and a set of oligonucleotide primers for rapid
diagnosis and to identify clinical isolates . Ranjana Srivastava, Deepak Kumar and Brahm S.
Srivastava.
1760/DEL/04, 15.9.05
6.
7.
A Process for the preparation of novel 4-Nitrobutanoate Inhibitors of Isocitrate Lyase from
Mycobacterium tuberculosis. Ranjana Srivastava, Brahm S. Srivastava M. K. Gupta, R. P. Tripathi, N.
Tiwari, D. Katiyar, R. Ravishankar .
0671/DEL/2006; 07.12.2006.
C-3 aryl and alkyl substituted 2,3-dideoxyglucopyranoside as potential antitubercular agent. Ram
sagar, M. Saquib, A.K. Shaw, A.N. Gaikwad, S.K. Sinha, A. Srivastava, V. Chaturvedi, M.Y. Krishnan,
Ranjana Srivastava, B.S. Srivastava.
0533 DEL/2006; 23.02.2006
Sequences submitted in EMBL database
Two Mycobacterium fortuitum insertion sequences IS219 and IS220. Sequence submitted to EMBL
Accession AJ 315500. 2002. These are new IS elements.
Technology Transferred
A new diagnostic reagent based on sequence specific M. tuberculosis DNA fragment: has been deveopled,
licensed and commercialized as MycoView MTB PCR Detection Kit by Biotron Healthcare (I) Pvt. Ltd. India
for early diagnosis of tuberculosis. The probe is a 1291 bp genomic DNA patented in USA, Europe and
India.